The Mesothelioma Applied Research Foundation would like to congratulate Dr. Lee M. Krug on his new position with Bristol-Myers Squibb (BMS), which he will be starting in August. He will be joining BMS as the Immuno-oncology Disease Head for Thoracic and GI Malignancies.
Dr. Krug will be leaving his position as an Associate Attending Physician in the Division of Thoracic Oncology, Department of Medicine at Memorial Sloan-Kettering Cancer Center in New York, New York.
“I promise to remain committed to the foundation and the search for the cure for mesothelioma,” said Dr. Krug.
Dr. Krug has investigated multimodality mesothelioma treatment approaches for patients with early stage malignant pleural mesothelioma. He led a multicenter U.S. trial of induction chemotherapy before extrapleural pneumonectomy, and he has a current study testing the feasibility of chemotherapy followed by pleural radiation. Dr. Krug also has a strong interest in novel therapeutics for patients with more advanced disease. He conducted a phase I trial with a WT-1 peptide vaccine, and he was awarded a grant from the Department of Defense to conduct a randomized phase II trial with this vaccine. He is also the principal investigator of an international, phase III trial of a histone deacetylase inhibitor, vorinostat. Dr. Krug led the committee for the National Comprehensive Cancer Network (NCCN) that established treatment guidelines for mesothelioma.
“Dr. Krug has an unwavering dedication to the mesothelioma field, and I am excited to see what new insight he will bring to the field with his new position at BMS,” stated Melinda Kotzian, Chief Executive Officer at the Meso Foundation.
We congratulate Dr. Krug and wish him the best in his new position.
The Meso Foundation would like to invite you to join us for the next installment of our Meet the Experts series: “New Frontiers in Surgery” on Thursday, January 30 at 9 PM Eastern time, featuring Joseph Friedberg, MD.
The teleconference will follow our usual format, with Mary Hesdorffer, Nurse Practitioner, as the moderator (you can listen to our previous installments here). We encourage all listeners to visit our Facebook page throughout the call to ask questions (email questions are also welcomed).
The teleconference is free, but does require that you RSVP in order to receive the call-in information. Please RSVP here.
Dr. Friedberg is a surgeon at the University of Pennsylvania and has an interest in diseases of the pleura. His protocol involves laser treatments and photodynamic therapy, on which he has published a promising study. He heads several investigational trials unique in the world to develop treatments for advanced cancers and malignant mesothelioma, including the development of a lung cancer vaccine. He frequently performs video thoracoscopic procedures for the treatment of a wide variety of chest diseases, and is skilled in both open and minimally invasive approaches to cancer surgery.
Dr. Friedberg will also be a speaker at this year’s International Symposium on Malignant Mesothelioma, taking place on March 5 – 7. Learn more about the Symposium and register today.
As the time for the Symposium draws near we are all filled with a sense of excitement. We strive to build upon the momentum gained in prior years and hope that we meet the expectations of both new and seasoned Symposium attendees. This year we will have a new roundtable composed of patients and healthcare providers. In this session I hope that we can identify the strengths that allow those with mesothelioma to continue to lead full and rewarding lives. What does it take to get from the early days of diagnosis to becoming a whole and healthy person who also happens to carry the diagnosis of mesothelioma? Knowing that you have an incurable disease, do you hope for the best and prepare for the worst? Is that even possible? I hope to explore these questions with patients. I also wish to open a dialogue about what it takes to be on the other end of the exam table, as a provider, charged with delivering the news, and then providing hope with reality. It is a fine balance and the providers we have chosen to partake in this discussion are known for their compassion and honesty. I hope that by exploring the patient and provider experience we can come away with better communication skills and a better understanding of what it takes to fill either set of shoes.
Physicians’ decision-making style and psychosocial outcomes among cancer survivors. Arora NK, Weaver KE, Clayman ML, Oakley-Girvan I, Potosky AL. Patient Educ Couns. 2009 Dec;77(3):404-12. Epub 2009 Nov 4.
Patient-centered communication and prognosis discussions with cancer patients. Shields CG, Coker CJ, Poulsen SS, Doyle JM, Fiscella K, Epstein RM, Griggs JJ. Patient Educ Couns. 2009 Dec;77(3):437-42. Epub 2009 Oct 9.
Measuring therapeutic alliance between oncologists and patients with advanced cancer: the Human Connection Scale. Mack JW, Block SD, Nilsson M, Wright A, Trice E, Friedlander R, Paulk E, Prigerson HG. Cancer. 2009 Jul 15;115(14):3302-11
Which patients improve: characteristics increasing sensitivity to a supportive patient-practitioner relationship. Conboy LA, Macklin E, Kelley J, Kokkotou E, Lembo A, Kaptchuk T. Soc Sci Med. 2010 Feb;70(3):479-84. Epub 2009 Nov 10
Bereavement: addressing challenges faced by advanced cancer patients, their caregivers, and their physicians. Kutner JS, Kilbourn KM. Prim Care. 2009 Dec;36(4):825-44. Review.
Mary Hesdorffer received her undergraduate degree at the College of New Rochelle in NY and went on to receive her Masters of Science at the same institution. She is fully credentialed as a Nurse Practitioner and has spent 11 years actively treating patients with mesothelioma. Mary has an expertise in the development and implementation of clinical trials. She has published in peer reviewed journals and has lectured nationally on the topics pertaining to mesothelioma with particular emphasis on clinical trials as well as symptom and disease management. She is well known to the Mesothelioma Applied Research Foundation‘s community having attended and spoken at many of our symposiums. Mary is passionate in her commitment to the treatment and management of this disease and hopes to increase awareness of the need to advance the science that will lead to a cure. She is available via phone or email to assist patients and caregivers as they move from chaos to control of this new situation they find themselves thrust into.
You can contact Mary by clicking here or by calling her at 877.363.6376 ext. 7275.